U.S. markets close in 1 hour 31 minutes

Eagle Pharmaceuticals, Inc. (EGRX)

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Add to watchlist
42.90+1.80 (+4.38%)
As of 2:27PM EDT. Market open.
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Bearishpattern detected
Fast Stochastic

Fast Stochastic

Previous Close41.10
Open41.49
Bid42.79 x 1100
Ask42.86 x 1100
Day's Range41.49 - 42.90
52 Week Range36.48 - 53.43
Volume44,548
Avg. Volume112,153
Market Cap562.805M
Beta (5Y Monthly)0.76
PE Ratio (TTM)40.43
EPS (TTM)1.06
Earnings DateAug 09, 2021 - Aug 13, 2021
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est47.33
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value
XX.XX
Overvalued
-23% Est. Return
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
View more
  • Eagle Pharmaceuticals Announces FDA Maintains Prioritization of ANDA for Vasopressin
    Business Wire

    Eagle Pharmaceuticals Announces FDA Maintains Prioritization of ANDA for Vasopressin

    WOODCLIFF LAKE, N.J., June 24, 2021--Eagle Pharmaceuticals, Inc. (Nasdaq: EGRX) ("Eagle" or the "Company") today announced that the U.S. Food and Drug and Administration ("FDA") has maintained Priority Review for the Company’s Abbreviated New Drug Application ("ANDA") for vasopressin. The Company’s response to the CRL was submitted on June 15, 2021. The FDA has assigned a GDUFA date of December 15, 2021, and the Company expects a commercial launch prior to year-end.

  • New Strong Sell Stocks for June 18th
    Zacks

    New Strong Sell Stocks for June 18th

    OEG, EAF, RARE, EGRX, and TELA have been added to the Zacks Rank #5 (Strong Sell) List on June 18, 2021

  • Eagle Pharmaceuticals Submits Response to Complete Response Letter from FDA for Vasopressin
    Business Wire

    Eagle Pharmaceuticals Submits Response to Complete Response Letter from FDA for Vasopressin

    WOODCLIFF LAKE, N.J., Jun 17, 2021--Eagle Pharmaceuticals, Inc. (Nasdaq: EGRX) ("Eagle" or the "Company") today announced that it has responded to the Complete Response Letter ("CRL") for its Abbreviated New Drug Application ("ANDA") for vasopressin received from the U.S. Food and Drug Administration ("FDA") in February 2021.